Par Drugs & Chemical Complete Financial Statements

In FYNone, Par Drugs & Chemical (PAR) reported revenue ₹102 Cr, net profit ₹10 Cr and EPS ₹7.90, with a net profit margin of 12.6% and ROE of 13.1%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV.

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 12.62% 2025 data
EBITDA Margin 21.36% 2025 data
Operating Margin 19.00% 2025 data
Return on Assets 10.92% 2025 data
Return on Equity 13.13% 2025 data

Balance Sheet Ratios

Current Ratio 13.75 2025 data
Debt to Equity 1.20 2025 data
Equity Ratio 83.19% 2025 data
Asset Turnover 0.87 2025 data

PAR Revenue, Net Profit & EBITDA — Year-on-Year Growth

PAR YoY (March 2025 vs Period) — revenue -1.0%, net profit -23.1%, EBITDA -22.7%, expenses +3.7%.

Revenue Growth
-1.0%
Year-over-Year
Net Profit Growth
-23.1%
Year-over-Year
EBITDA Growth
-22.7%
Year-over-Year
Expense Growth
+3.7%
Year-over-Year
Assets Growth
+16.7%
Year-over-Year
Equity Growth
+15.1%
Year-over-Year
Liabilities Growth
+16.7%
Year-over-Year
Operating Cash Flow Growth
-20.0%
Year-over-Year
Investing Cash Flow Growth
-316.7%
Year-over-Year

PAR Income Statement — Revenue, EBITDA & Net Profit

Par Drugs & Chemical revenue ₹102 Cr, EBITDA ₹17 Cr, net profit ₹10 Cr, EPS ₹7.90 (None) — net profit margin 12.6%.

Periods ₹ Crores
Particulars None March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017
Revenue 102 103 96 96 75 61 56 46 42 49
Expenses 85 82 73 78 59 45 46 38 34 40
EBITDA 17 22 23 18 16 16 10 8 8 9
Operating Profit Margin % 13.00% 19.00% 24.00% 19.00% 22.00% 26.00% 17.00% 18.00% 19.00% 18.00%
Depreciation 4 4 3 3 3 3 3 3 3 3
Interest 0 0 0 0 1 1 1 2 2 3
Profit Before Tax 13 18 20 15 13 15 6 3 3 3
Tax 3 5 5 4 4 3 1 1 1 2
Net Profit 10 13 15 11 9 12 5 3 2 2
Earnings Per Share (₹) 7.90 10.86 11.78 9.21 7.49 18.87 7.75 5.60 5.64 6.50

Related Pages for Par Drugs & Chemical

Additional stock information and data for PAR

PAR stock overview
Par Drugs & Chemical intrinsic worth

PAR Balance Sheet — Assets, Liabilities & Shareholders' Equity

PAR total assets ₹119 Cr, total equity ₹99 Cr, total liabilities ₹119 Cr (2025) — ROE 13.1%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017
ASSETS
Total Assets 119 102 89 79 76 60 51 54 56
Current Assets 55 60 49 44 41 24 14 14 14
Fixed Assets 39 41 38 34 30 34 36 39 42
Capital Work in Progress 0 0 0 0 5 1 0 0 0
Investments 25 0 0 0 0 0 0 0 0
Other Assets 55 60 50 44 42 25 15 15 15
LIABILITIES
Total Liabilities 119 102 89 79 76 60 51 54 56
Current Liabilities 4 4 4 4 8 9 10 16 17
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 99 86 71 60 52 41 29 21 20
Share Capital 12 12 12 12 6 6 5 9 9
Reserves & Surplus 87 73 59 48 46 35 25 13 11

PAR Cash Flow Statement — Operating, Investing & Financing

Par Drugs & Chemical operating cash flow ₹16 Cr, investing ₹-25 Cr, financing ₹0 Cr, net cash flow ₹-9 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 16 20 13 8 12 8 2 4 9 7 9
Investing Activities -25 -6 -7 -3 0 -2 0 -1 -2 0 0
Financing Activities 0 0 0 -10 2 1 -2 -4 -8 -6 -9
Net Cash Flow -9 14 6 -5 14 7 0 0 -1 1 -1